NCT03701282 2026-03-18
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
Janssen Research & Development, LLC
BeOne Medicines
AstraZeneca
Hoffmann-La Roche
Acerta Pharma BV
German CLL Study Group
Acerta Pharma BV